Findings identify NSUN2 as a critical orchestrator of T-cell exclusion in LUAD and serves as both a candidate predictive biomarker for ICI failure and a promising druggable target for immunotherapy resistance.
Abstract
Insufficient T-cell infiltration is a major barrier to the efficacy of immune checkpoint inhibitors (ICIs) in lung adenocarcinoma (LUAD). We aimed to investigate how the tumor-intrinsic m5C methyltransferase NSUN2 shapes the immune landscape of LUAD. Nsun2 conditional knockout mice and syngeneic mice models were employed. Single-cell RNA sequencing (scRNA-seq) and m5C sequencing were performed to elucidate the downstream pathway regulated by NSUN2. LUAD specimens from patients receiving neoadjuvant immunotherapy were used to assess the correlation between NSUN2 expression and immune infiltration. Elevated tumoral NSUN2 expression was correlated with a marked lack of CD8+ T-cell infiltration and immunotherapy resistance. Mechanistically, NSUN2 enhances the translation of histone deacetylase HDAC8 in an m⁵C-YBX1-dependent manner, which in turn directly represses the transcription of the chemoattractant CCL5, thereby impairing CD8+ T-cell recruitment into the tumor. NSUN2 depletion reversed this immunosuppressive axis and converted immunologically “cold” tumors into “hot”. Tumor-targeted liposomes loaded with the NSUN2 inhibitor synergized with anti-PD-1 therapy to induce significant tumor regression. Our findings identify NSUN2 as a critical orchestrator of T-cell exclusion in LUAD. It serves as both a candidate predictive biomarker for ICI failure and a promising druggable target. Targeting NSUN2 offers a potential strategy to overcome immunotherapy resistance and improve clinical outcomes in LUAD patients.
It is suggested that the SHMT2–lactate–CAF axis contributes to the metabolic–stromal regulation of T-cell exclusion and may represent a potential therapeutic target for improving the response of immune-excluded HNSCC to PD-1 blockade.
He-Lei Yan, Lu Wang, Zhen Li et al.· Cell Death & Disease· 0 citations
The H3K4me3-HNRNPC-CD24 axis is unveiled as a central epigenetic and post-transcriptional regulatory pathway that coordinately drives HCC stemness and immune evasion, nominating HNRNPC-targeted nanotherapy as a promising strategy for advanced HCC.
D. Ye, Xue-Yin Pan, Jia-Qing Chen et al.· Cancer Letters· 0 citations
The role of non-histone lysine methylation in tumorigenesis has attracted increasing attention, and the dysregulated “writers”, “erasers” and “readers” of it are promising therapeutic targets. In this study, we demonstrated that lysine-specific demethylase 4B (KDM4B) was significantly upregulated in renal cell carc...
Zi-Ran Dai, Ming-Xiao Zhang, Hao Zhou et al.· Cell Death & Disease· 1 citation
It is indicated that FSTL1 represents a promising immunomodulatory target and highlight its potential as a therapeutic target to reprogram the immunosuppressive microenvironment and improve the efficacy of GC immunotherapy.
Ming Yang, Rong-Fei Wang, Xiao Wang et al.· Journal of Translational Med...· 0 citations
PPP1R14B (PP1 regulatory inhibitor subunit 14B) was overexpressed in PCa and associated with poor prognosis, promoting PCa cell proliferation, suppressing apoptosis, and correlating with increased tumor purity but reduced CD8+ T-cell infiltration.
Jie Yang, Chuan Zhou, Wen-Bo Zhang et al.· Journal of Pathology· 0 citations